GLP-1 dulaglutide dec renal and cardiovasc events
Another
industry-sponsored study found benefit for a GLP-1 agonist on renal and
cardiovascular outcomes, this time with dulaglutide in the REWIND study.
RENAL
BENEFITS:
(see dm dulaglutide dec renal events lancet2019 in dropbox,
or doi.org/10.1016/S0140-6736(19)31150-X
Details:
--
9901 participants from 371 sites in 24 countries in this randomized
double-blind trial, comparing dulaglutide injections of 1.5 mg vs placebo
--
mean age 66, 46% women, 76% white, duration of diabetes 11 years, median A1c
7.2%, BMI 32, blood pressure 137/78,
--
meds: metformin 81%, sulfonylureas 46%, insulin 24%, ACE inhibitors 50%,
ARB’s 34%, ACE-I or ARB 81%
--
baseline: 8% had macroalbuminuria, 27% microalbuminuria, mean urinary
albumin/creatinine ratio UACR, 2 mg/g, mean eGFR 77 (22% had eGFR
<60), creatinine 0.95 mg/dL
--
primary composite outcome: 1st occurrence of nonfatal MI, nonfatal
stroke, or death from cardiovascular causes
--
secondary outcome composite of microvascular outcomes (eye and renal) and
safety outcomes
--
participants took the dulaglutide 82% of the follow-up time
--
this was an exploratory analysis assessing the renal component of the composite
microvascular outcomes: 1st occurrence of new macroalbuminuria
(UACR, >30 mg/g), sustained decline of eGFR > 30% from baseline, or
chronic renal replacement therapy
--
UACR and eGFR were measured every 12 months
--
follow-up 5.4 years
Results:
--
over 51,820 person-years, renal outcome developed in:
-- dulaglutide group: 848 (17.1%), incidence rate of 3.5 per 100
person-years
-- placebo : 970 (19.6%), incidence rate of 4.1 per 100 person-years
-- 15% lower with dulaglutide, HR 0.85 (0.77-0.93), p=0.0004
--
clearest effect was for new macroalbuminuria, at 23% lower rate, HR 0.77
(0.68-0.87), p<0.0001. The graph showed a decrease over the 1st
year of treatment, then the curves paralleled each other
--
sustained decline of eGFR>30%: almost clinically significant 11% decrease,
HR 0.89 (0.78-1.01), p=0.066. This reflected
decreases of 4.32 ml/min/1.73 m2 for dulaglutide and 4.75 for
placebo over the course of the study. The graphs show pretty linear decrease
continuing over time
--
chronic renal replacement therapy: nonsignificant difference (all 3 of these
outcomes had similar 25% decreases, though for chronic renal replacement it was
far from statistically significant, not surprisingly given how renally-healthy
this cohort was)
--
at the final visit, fewer people on dulaglutide were taking drugs that are
known to improve renal outcomes, including SGLT2 inhibitors (5.3% vs 7.3%), or
ACE inhibitors/ ARBs (75.8% vs 77.6%)
--
subgroup analysis: very similar dulaglutide benefits if eGFR <60 or >60,
normo- vs micro- or macroalbuminuria, or ACE inhibitor/ARB use, as well as
subgroups defined by age, sex, duration of diabetes, and baseline A1c.
--
Dulaglutide was also associated with 25% reduced incidence of sustained eGFR of
>40% or >50%
--
the overall absolute risk difference: 1 composite renal outcome would be
prevented for every 31 similar people with diabetes treated with dulaglutide
for median of 5.4 years
Commentary:
--
in general, diabetic kidney disease (as defined by an eGFR <90) affects 40%
of people with diabetes; and this is an independent risk factor for
cardiovascular disease, hypertension, retinal disease, and premature death
--
and, diabetes is responsible for 45% of people who develop end-stage renal
disease
-- current
medical interventions to decrease the rate of diabetic kidney disease
are primarily through intensive glucose control and blood pressure
lowering. In addition, use of ACE inhibitors or ARBs and SGLT2 inhibitors help.
--
Other studies have found that the GLP-1’s liraglutide in semaglutide decrease
predefined composite renal outcomes overall, as well as in people with an
already reduced eGFR.
--
A recent report of the AWARD-7 study (see dm dulaglut vs insulin renal
failure lancetdiabendo2018 in dropbox, or doi.org/10.1016/S2213-8587(18)30104-9) found
that comparing dulaglutide vs insulin glargine in patients with stage III
or IV CKD, and achieving similar A1c results, found a reduced
decline in eGFR with dulaglutide in this one year trial. The REWIND study
found a pretty-close-to statistically significant effect on eGFR, though the
patients in this study had much less renal disease to begin with, and also
had pretty well controlled diabetes at the start, so
were at much lower risk of a renal decline
--
part of the explanation for renal protection is likely that the baseline A1c
and systolic blood pressure decreased more in those on dulaglutide.
Controlling for the likely contributions of these changes, the effect of
dulaglutide on renal outcomes was attenuated by up to 26% after accounting for
the effects of the A1c change and up to 15% after the effect on systolic blood
pressure. This suggests that other factors are involved in the renal
protection, and GLP-1 agonists are known to reduce inflammation, oxidative stress,
and preserve endothelial function
---------------------------------------------------------------------------------------------------------
CARDIOVASCULAR
BENEFITS: see dm
dulaglutide dec cardiovasc lancet2019 in dropbox,
or doi.org/10.1016/S0140-6736(19)31149-3
Details: as above with the
following differences:
--
32% had previous cardiovascular disease (ie 1/3 of the patients were assessed
for secondary prevention; 2/3 primary prevention: a pretty healthy cohort since
about 80% of diabetics die from cardiovascular disease)
--
primary outcome was 1st occurrence of composite endpoint of nonfatal
MI, nonfatal stroke, or death from cardiovascular causes
--
secondary outcomes: as in renal, but also hospital admission for unstable
angina
Results:
--over
the 5.4 years, primary composite outcome:
-- dulaglutide: 594 people (12.0%), incidence rate of 2.4 per 100 person-years
-- placebo: 663 people (13.4%), incidence rate of 2.7 per 100 person-years
-- 12% decrease, HR 0.88 (0.79-0.99), p=0.026
--
consistent effect was found for all 3 components of the primary outcome, though
the only one to reach statistical significance was for nonfatal stroke, with
24% decreased, HR 0.76 (0.61-0.95),p=0.017
--
subgroup analysis showed similar reductions in primary outcome for those with
and without prior cardiovascular disease, those with A1c > vs <7.2%, and
in those analyzed according to age, sex, duration of diabetes, and BMI. However
I could find no specific analysis of those on vs off sulfonylurea/insulin
therapy
--
for every 60 people with diabetes and additional cardiovascular risk factors
treated for a 5.4 years with dulaglutide, one cardiovascular event was
prevented; for those with a previous cardiovascular event (secondary prevention), it was one in 18
--
all-cause mortality did not differ between the groups, 10.8% in dulaglutide,
12% of placebo, HR 0.90 (0.80-1.01) ,p=0.67
--
no difference in hospitalizations for heart failure
Commentary:
--
This trial also involved quite low risk patients, the average cardiovascular
incidence of participants on placebo was 2.7%
--
it was notable that stroke reduction was the most significant of the
cardiovascular outcomes assessed
--
one benefit of this trial is that its duration was significantly longer than
that for the SGLT2 studies
--
One limitation is that about 25% of patients were not taking the study drug
with a full 5.4 years
-- Given my evident preference for GLP-1
agonists over SGLT2’s (see multiple prior blogs, including http://gmodestmedblogs.blogspot.com/2019/06/diabetes-oral-semaglutide-better-than.html
and https://gmodestmedblogs.blogspot.com/2019/06/diabetes-guideline-update-pushing-sglt.html),
I should add that there seems to be a synergy with the combo: (see dm semaglut
added to sglt2 lancet2019 in dropbox, or
doi.org/10.1016/S2213-8587(19)30066-X), where adding semaglutide 1.0 mg vs
placebo to an SGLT2 inhibitor led to an added 1.42 percentage point decrease in
A1c.
so,
--
this REWIND trial did find a benefit for the GLP-1 dulaglutide for both renal
and cardiovascular outcomes, even though these patients at baseline were at
quite low risk of a significant complication
--
i bring these articles up because they are confirmatory of others suggesting
benefit of GLP-1’s, but this time in a much healthier population with a longer
life expectancy and therefore a likely increasingly improving benefit over
their anticipated longer lifespans.
--
Again, this supports the concept of starting with metformin and then adding a
GLP-1 as a second medication, even in those with relatively well-controlled
diabetes (this study started with mean A1c of 7.2%) and without pre-existing
comorbidities.
geoff
If you would like to be on the regular
email list for upcoming blogs, please contact me at gmodest@uphams.org
For access to
the dropbox, go to link: https://www.dropbox.com/sh/0bmvtita8mzms11/XDTwHySFFg
Then go to
"clinic", then to either "clinical stuff" for articles, or
"powerpt presentations" for
the powerpoint presentations
to get access to all of the
blogs:
2. click on 3 parallel lines
top left, if you want to see blogs by category, then click on
"labels" and choose a category
3. or you can just click on
the magnifying glass on top right, then type in a name in the search box
and get all the blogs with that name in them
please feel free to circulate
this to others. also, if you send me their emails, i can add them to the list
Comments
Post a Comment
if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org